Trial reportInternational ophthalmology2025
Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors).
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the intraocular pressure (IOP) lowering effect and safety of topical netarsudil 0.02% once daily with topical ripasudil 0.4% twice daily in primary open angle glaucoma (POAG) patients.
methodsA prospective, comparative, randomized study conducted on 140 eyes of patients diagnosed to have POAG, in a tertiary care hospital of Northern India. Patients divided into groups, A and B in a 1:1 ratio and were treated with ripasudil 0.4% or netarsudil 0.02% respectively and followed up. The mean diurnal IOP noted at 3rd week and 3rd month comparing it from baseline values, with their side effects.
resultsAt 3rd month, meandiurnal IOP for ripasudil 0.4% group ranged from 19.22 to 20.69 mmHg whereas for netarsudil group it was 17.11-18.47 mmHg, an intergroup statistically significant difference in IOP of 2.3 mmHg (p < 0.0001) noted. At 3
conclusionTopical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG.
Indexed as
Identifiers
40504269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.